covid cicada variant

What You Need to Know About the New 'Cicada' COVID Variant Spreading Across Australia

As winter tightens its grip across Australia, a new chapter in the ongoing story of the SARS-CoV-2 virus has emerged—one that’s capturing global attention and prompting renewed public health vigilance. The latest buzz? A highly mutated strain known as BA.3.2, nicknamed the “Cicada variant” by media outlets and some scientists. First identified in South Africa in late 2024, this variant is now being monitored closely by health authorities worldwide—including in Australia—due to its unusual mutation profile and rapid spread.

So what does this mean for Australians? Is it time to panic? And more importantly, should you adjust your routine? Let’s break down everything we know so far—based on verified reports from trusted sources—and separate fact from speculation.

What Is the Cicada Variant?

Officially designated SARS-CoV-2 Omicron subvariant BA.3.2, the “Cicada” name comes from its emergence pattern: like periodic cicadas emerging after years underground, the variant surfaced in late 2024 before largely disappearing—only to reappear with significant genetic changes. Unlike seasonal flu or even earlier Omicron waves, BA.3.2 carries an unusually high number of spike protein mutations—the part of the virus that helps it enter human cells and evade immune defenses.

According to the U.S. Centers for Disease Control and Prevention (CDC), which first flagged the variant as a “variant under monitoring,” BA.3.2 has been detected in at least 25 U.S. states and 23 countries globally, including several Australian jurisdictions. While localised data remains limited, preliminary genomic surveillance suggests it may be gaining traction here too.

“The sheer number of mutations in BA.3.2 raises concerns about potential immune escape—meaning prior infection or vaccination might offer less protection than expected,” says Dr. Sarah Chen, virologist at the Peter Doherty Institute for Infection and Immunity in Melbourne.

Recent Developments: Timeline of Key Events

Here’s a chronological overview of how the situation unfolded—based on verified reporting:

• November 2024: BA.3.2 first identified in South Africa through wastewater surveillance and clinical sequencing. Initial cases clustered among travellers returning from Southern Hemisphere hotspots.

• December 2024 – January 2025: Reports emerge in U.S., UK, and Europe confirming community transmission. Scientific American notes early signs of increased transmissibility compared to dominant strains like XBB.1.5.

• February 2025: WHO adds BA.3.2 to its “under monitoring” list. CDC begins issuing alerts to laboratories and clinicians in the U.S.

• March 2025: Multiple Australian states report isolated cases linked to overseas travel or imported goods. NSW Health confirms one cluster in Sydney involving household contacts.

• April 2025: TGA (Therapeutic Goods Administration) updates guidance for PCR tests, noting that current commercial kits remain effective at detecting BA.3.2.

• May 2025: Federal Department of Health advises healthcare providers to increase genomic sequencing capacity amid rising international concern.

Note: As of now, there are no confirmed widespread outbreaks of BA.3.2 in Australia. All reported cases appear sporadic or small clusters.

Why Is This Variant Called ‘Cicada’?

The nickname “Cicada” was coined by journalists and scientists referencing both the insect’s life cycle and the variant’s behavior. Like periodical cicadas that emerge en masse every 17 years, BA.3.2 appeared suddenly in late 2024 after seeming dormant since early 2024—then surged rapidly across borders.

Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, told USA Today:

“It’s not just another variant. Its mutation load is extraordinary. We’re seeing combinations we haven’t seen before—some that affect receptor binding, others that may interfere with antibody recognition.”

This biological oddity explains why researchers are treating it seriously—even if case numbers remain low in Australia.

How Does BA.3.2 Compare to Other Variants?

To understand the risk, let’s compare key features:

While vaccines still reduce severe outcomes—even against newer variants—the sheer mutational burden of BA.3.2 means neutralising antibodies from prior shots or infections may be less effective. However, T-cell immunity (from past exposure) likely provides broader, albeit reduced, protection.

Symptoms: What Should You Watch For?

Based on early case reports from the U.S. and UK, symptoms associated with BA.3.2 appear similar to other Omicron subvariants—but with subtle differences:

• Fatigue and headache
• Sore throat and runny nose
• Mild fever or chills
• Muscle aches
• Less common: loss of taste/smell (though still possible)

Importantly, many infected individuals report milder illness than during earlier pandemic waves—possibly due to accumulated population immunity or the variant’s adaptation to humans.

“We’re not seeing hospitalisations spike dramatically yet,” says Associate Professor James Trauer from Monash University. “But that could change if transmission accelerates.”

If you develop respiratory symptoms—especially after recent travel or contact with someone unwell—consider getting tested regardless of vaccination status.

Current Impact in Australia

As of May 2025, Australia’s official stance remains cautious but not alarmist.

• No national surge in cases attributed to BA.3.2.
• Genomic sequencing coverage is increasing, particularly in Victoria and Queensland.
• Hospitals report stable admissions; no ICU overflows linked to the variant.
• Travelers from high-risk regions are advised to self-isolate if symptomatic.

However, experts warn complacency is dangerous. With international borders fully open and summer travel approaching, importation risk remains elevated.

“We’ve learned the hard way that ignoring variants leads to bigger problems later,” warns Dr. Chen. “Preparation now saves lives later.”

Future Outlook: Scenarios and Recommendations

So where could this go?

Possible Outcomes:

1. Controlled Spread: BA.3.2 circulates quietly, possibly becoming dominant by winter 2025—but causes mostly mild disease due to existing immunity.
2. Accelerated Transmission: Widespread uptake triggers a modest wave, straining healthcare systems slightly.
3. Vaccine Update Triggered: Regulators fast-track a new bivalent booster targeting BA.3.2.

Given historical patterns, option #1 seems most likely—but no one can predict viral evolution.

What Should Australians Do Now?

• Stay up to date with recommended COVID-19 vaccinations (including boosters).
• Wear masks in crowded indoor settings, especially during peak flu season.
• Improve ventilation at home and work.
• Get tested promptly if symptomatic—even if previously infected.
• Monitor official channels: Follow updates from Health.gov.au and state health departments.

“This isn’t the end of the pandemic,” concludes Dr. Trauer. “It’s the next phase—where we live with the virus responsibly, without letting fear dictate our lives.”

Final Thoughts

The emergence of the Cicada variant serves as a reminder that SARS-CoV-2 continues to evolve—and that vigilance matters. But it also underscores how far we’ve come: better diagnostics, smarter public health responses, and a more informed society.

For Australians, the message is clear: stay alert, stay protected, and don’t underestimate the power of simple precautions. After all, even the buzziest bug can’t survive the collective resilience of a community that knows how to act.

Stay safe, and keep checking those official updates—because when it comes to viruses, knowledge truly is your best defense.